Real-World Outcomes With EGFR-TKIs in Early-Stage EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Natalie Vokes examine how outcomes with adjuvant EGFR tyrosine kinase inhibitors translate from clinical trials into real-world practice in early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Vokes discusses key differences between clinical trial populations and patients seen in routine care, including older age, comorbidities, and variations in performance status. Despite these differences, she notes that real-world experiences have generally been consistent with trial findings, particularly in terms of tolerability and clinical benefit. The conversation also highlights the importance of proactive adverse event management and individualized care to help patients remain on therapy. Dr. Vokes emphasizes that careful patient selection and close monitoring are essential to achieving outcomes comparable to those seen in trials such as ADAURA. This segment reinforces the relevance of clinical trial data while acknowledging the nuances of applying these findings in everyday practice.